7th National Formulary of India launched; Biovigilance Programme of India approved
On 21 September 2026, MoS Health Anupriya Patel launched the 7th edition of the National Formulary of India and announced Government approval of the Biovigilance Programme of India, at the 6th National Pharmacovigilance Week in New Delhi.
Summary
The 7th National Formulary of India was launched at a programme organised by the Indian Pharmacopoeia Commission (IPC), along with a guidance document for hospitals on medical device-related adverse events and the ADR-PvPI 2.0 app for iOS. Under the newly approved Biovigilance Programme of India, the IPC will lead monitoring of adverse events linked to medicines and biological products used in organ and tissue transplantation. Anupriya Patel said India has risen from 123rd (2009–2014) to 8th globally in contributions to the WHO patient safety database, with about 1,150 ADR reporting centres now operating. The 6th National Pharmacovigilance Week (17–23 September) has the theme 'Promoting Rational Use of Medicines through Pharmacovigilance: A Step Towards Safer Healthcare'.
Key facts
- Launched
- 7th edition, National Formulary of India (also on NFI Online)
- New programme
- Biovigilance Programme of India — IPC to monitor adverse events in organ and tissue transplantation
- Global ranking
- India 8th in contributions to WHO patient safety database (from 123rd in 2009–2014)
- Network
- About 1,150 ADR reporting centres
- Event
- 6th National Pharmacovigilance Week, 17–23 Sep 2026, organised by IPC
Practice MCQs 4 questions
Which body will lead the newly approved Biovigilance Programme of India?
Show answer
Correct answer: D — Indian Pharmacopoeia Commission
The Indian Pharmacopoeia Commission (IPC) will play the lead role under the Biovigilance Programme of India.
The Biovigilance Programme of India will monitor adverse events linked to which area?
Show answer
Correct answer: B — Organ and tissue transplantation
The programme covers medicines and biological products used in organ and tissue transplantation, including those given to donors and recipients.
As stated in September 2026, what is India's global position in contributions to the WHO patient safety database?
Show answer
Correct answer: A — 8th
India has moved from 123rd during 2009–2014 to 8th globally.
Consider the following about the launch on 21 September 2026: 1. The 7th edition of the National Formulary of India was launched at the 6th National Pharmacovigilance Week. 2. The National Pharmacovigilance Week is organised by the National Medical Commission. Which of the above is/are correct?
Show answer
Correct answer: A — 1 only
Statement 1 is correct. Statement 2 is wrong: the programme was organised by the Indian Pharmacopoeia Commission (IPC).